.png){kind=icon}
.png){kind=icon}
Return
Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective
.png){kind=icon}
OA
AI
J
M
V
A
C
M
N
M
J
A
S
L
S
E
C
J
S
C
DOI：10.1016/j.ctrv.2026.103177.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Ramucirumab and Apatinib: the only anti-angiogenics to improve OS in GC. • Anti-angiogenics + anti-PD(L)1: no survival gain to date. • Bispecific PD(L)1/VEGF Abs: Higher efficacy, lower toxicity. • Biomarkers are the keys to unlock anti-angiogenesis efficacy.
Keywords:
Gastric cancer
antiangiogenic
Immune checkpoint inhibitor
Multi-target Kinase inhibitor
Bispecific antibodies
Biomarkers
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
10.5
Papers:
2.8K
Citations:
1.3W
Organization
Cited Papers